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Th17-derived Th1 lymphocytes, termed nonclassic, differ from classic Th1 cells because of the presence of retinoic acid orphan
receptor (ROR)C2 and the surface expression of CD161 and CCR6. We demonstrate in this article that nonclassic Th1 cells, like
Th17 cells, have a marked RORC2 and IL17A demethylation, whereas classic Th1 cells exhibit a complete methylation of these
genes. The analysis of RORC2 DNA methylation in the CD4+CD161+ and CD4+CD1612 naive Th subsets from umbilical cord
blood surprisingly revealed comparable hypermethylation levels. PCR analysis at the single-cell level revealed that RORC2 mRNA
was expressed by none of the CD4+CD1612 and present only in a minority of CD4+CD161+ naive Th cells. These findings provide
two important novel observations on the physiology of human Th17 cells: 1) they confirm at the epigenetic level the origin of
nonclassic Th1 cells from Th17 cells, also identifying in the RORC2 and IL17A methylation status a novel tool for their distinction
from classic Th1 cells, and 2) they demonstrate that RORC2-expressing cells are only a minority in the subset of CD4+CD161+
naive Th cells, which are known to contain all Th17 cell precursors. The Journal of Immunology, 2015, 194: 3116–3126.
A
ctivated CD4+ T cells can be divided into functionally
distinct subsets on the basis of their cytokine production
and their specific transcription factor expression: Th1
secrete IFN-g, express the transcription factor T-bet (T-box
expressed in T cells, TBX21), and protect the host against intra-
cellular infections; Th2 cells secrete IL-4, IL-5, and IL-13, express
the transcription factor GATA-3, and mediate host defense against
helminths; and Th17 cells, which selectively produce IL-17A,
express the transcription factor retinoic acid orphan receptor
(ROR)C2 and are critical for the host defense against extracellular
pathogens (1–4). Moreover, a subset of human IL-17A–producing
CD4+ T cells was found also to produce IFN-g (Th17/Th1), and
both Th17 and Th17/Th1 cells exhibited plasticity toward the Th1
profile when cultured in the presence of IL-12 (4). Similar findings
were then also reported in some murine models (5–7), suggesting
that both human and murine Th17 cells probably represent a
transient phenotype (8). In a previous study, we also showed that
virtually all human memory Th17 cells are contained within the
CD161+ fraction of both circulating and tissue-infiltrating CD4+
T cells, and originate from CD161+ precursors present in umbil-
ical cord blood (UCB) and newborn thymus (9), a finding that has
not been reported in mice. In humans, Th1 cells that derive from
the shifting of Th17 cells were defined as nonclassic Th1 cells (8,
10) because they express RORC2, CD161, and CCR6, as do Th17
cells (9–11).
Tissue- and cell-specific transcriptional regulatory programs
are acquired during various stages of cellular differentiation and
must persist into the cellular progeny to maintain the specialized
functions of the cells in a particular tissue. Covalent modifications
to histones and DNA, referred to as epigenetic modifications, are
used to regulate transcription factor and polymerase access to
transcriptional regulatory elements in chromatin. Epigenetic modifi-
cation of chromatin permits the cells to retain acquired transcrip-
tional regulation throughout cell division, providing a cellular
identity to the progeny (12, 13). In addition, the development
of distinct Th cell lineages has been shown to involve heritable
epigenetic changes that regulate the expression of both lineage-
specific transcription factors (including TBX21, RORC2, and
GATA3) and cytokines (including IFN-g, IL-17A, and IL-4)
(14–16).
In this study, we examined the methylation patterns of regions of
interest (ROI), identified by sequence homology analysis between
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mice and humans, of the human genes RORC2 (17), TBX21, IL17A
(17), IL17F (18), and IFNG (19) in either human T cell clones or
circulating freshly isolated CD4+ T cells, isolated from both pe-
ripheral blood (PB) of healthy subjects and synovial fluid (SF) of
juvenile idiopathic arthritis (JIA) patients, characterized by the
following phenotypes: Th17, Th17/Th1, nonclassic (Th17-
derived), and classic Th1. We further analyzed the methylation
changes of the above-mentioned ROI in Th17 clones during the
in vitro polarization of Th17 into the nonclassic Th1 phenotype.
Our results demonstrate the existence of a strict relationship be-
tween Th17 and nonclassic Th1 cells, and support the concept that
nonclassic and classic Th1 cells belong to two distinct cell line-
ages. These findings also identify the demethylated status of
RORC2 and IL17A ROI as useful markers of the “Th17 mem-
bership.” Finally, the study of RORC2 downstream ROI methyl-
ation status, as well as the PCR analysis at the single-cell level of
the CD4+CD161+ T cell subset that contains all Th17 precursors
(9), demonstrated the heterogeneity of this cell population, only
partially composed of cells expressing RORC2, that is, potentially
able to differentiate into Th17 cells. Altogether our data provide
other important pieces in the puzzle of human Th17 cell physi-
ology and heterogeneity.
Materials and Methods
Subjects
The PB samples were obtained from seven healthy donors. SF samples were
collected from four JIA patients during routine therapeutic arthrocentesis.
UCB samples were obtained from eight donors. The procedures followed in
this study were in accordance with the ethical standards of the Regional
Committee on Human Experimentation.
Reagents
The medium used was RPMI 1640 (Seromed, Berlin, Germany), supple-
mented with 2 mM L-glutamine, 1% nonessential amino acids, 1% pyru-
vate, 2 3 10-5 M 2-ME (Life Technologies Laboratories, Grand Island,
NY), and 10% FCS (Euroclone). The following unlabeled or fluoro-
chrome-conjugated mouse anti-human mAbs were used to stain cells:
CD3, CD4, CD8, CD161, CCR6, CD45RA, CD45RO, CD31, IFN-g, and
isotype-matched control Abs (BD Biosciences, Mountain View, CA), IL-17A
(eBioscience, San Diego, CA), and CD161 (Miltenyi Biotec, Bergisch
Gladbach, Germany). PMA, ionomycin, brefeldin A, and saponin were from
Sigma-Aldrich (St. Louis, MO). IL-1b, IL-6, IL-12, IL-23, and TGF-b
were purchased from R&D Systems.
T cell recovery and expansion
Mononuclear cell (MNC) suspensions were obtained from PB, SF, and UCB
by centrifugation on Ficoll-Hypaque gradient. PB CD4+ T cells were
negatively selected by high-gradient magnetic cell sorting (Miltenyi Bio-
tec), as described by Cosmi et al. (9) and were then further divided into
CD161+ and CD1612 by immunomagnetic cell sorting (Miltenyi Biotec).
PB CD4+CD161+ and CD4+CD1612 T cell populations were further sub-
divided in CCR6+ and CCR62 cell fractions by FACSAria (BD Bio-
sciences) and then cultured under limiting dilution to obtain Th17 and Th1
clones, classified by flow cytometry for intracellular staining of IL-17A or
IFN-g cytokines (4). We stimulated in vitro four selected pure Th17 cell
clones in the presence of allogeneic feeder cells, PHA (0.001% v/v) plus IL-
2 (50 IU/ml), and the Th1-polarizing cytokine IL-12 (2 ng/ml). After 2 wk
of in vitro activation, a significant proportion of cells started to produce
IFN-g. The Th17/Th1-polarized Th17 clones were then sorted by FACS-
Aria into CD4+IL-17A+IFN-g2, CD4+IL-17A+IFN-g+, CD4+IL-17A2
IFN-g+ T cell subpopulations, using the cytokine secretion assay, as de-
scribed below. The CD4+IL-17A2IFN-g+ cell fraction of three of these
polarized clones was then cultured again for 2 wk in the presence of IL-2
(50 IU/ml) alone, or with the addition of IL-1b (10 ng/ml) and IL-23
(20 ng/ml) or with IL-1b, IL-6 (2 ng/ml), IL-23, and TGF-b (5 ng/ml).
PB CD4+ naive T cells were obtained as CD45RO2CD45RA+CD31+ by
FACSAria. UCB CD4+ T cells, negatively selected by high-gradient mag-
netic cell sorting (Miltenyi Biotec), were then pooled from eight samples
and further divided into CD161+ and CD1612 T cell fractions by FACS-
Aria. The same sorting strategy was followed to obtain CD4+CD161+ and
CD4+CD1612 single cells from two independent UCB samples.
Cytokine secretion assay
PB and SF CD4+ were negatively selected by high-gradient magnetic cell
sorting and further divided into CCR6+ and CCR62 cells by immuno-
magnetic cell sorting (Miltenyi Biotec), then were stained with anti-CD161
PE-Cy7, stimulated with PMA–ionomycin, recovered after 3.5 h, washed,
and then stained with IFN-g and IL-17A catch reagents (Miltenyi Biotec),
according to the manufacturer’s instructions. Following an additional
45 min of incubation (37˚C, 5% CO2), cells were stained with anti-CD3–
Pacific Blue, -IL-17A–APC, and -IFN-g–FITC; analyzed; and sorted by
FACSAria. PB samples were divided into CD4+CCR6+CD161+IL-17A+
IFN-g2, CD4+CCR6+CD161+IL-17A+IFN-g+, CD4+CCR6+CD161+IL-
17A2IFN-g+, and CD4+CCR62CD1612IL-17A2IFN-g+ T cell subsets,
whereas SF samples were divided into CD4+CCR6+CD161+IL-17A2IFN-g+
and CD4+CCR62CD1612IL-17A2IFN-g+ T cell subsets. Because of the
low numbers of recovered cells, SF cell fractions were then expanded
in vitro in the presence of IL-2 (50 IU/ml).
DNA methylation analysis
Genomic DNA was extracted and subsequently bisulfite was converted
using the DNA Blood Mini Kit (QIAGEN, Hilden, Germany) and EZ DNA
Methylation-Gold Kit (ZymoResearch, Irvine, CA), respectively, according
to the manufacturer’s instructions. DNA methylation of the ROI was
assessed by pyrosequencing of bisulfite-specific PCR products using
standard procedures (Varionostic, Ulm, Germany), as described previously
by Dong et al. (19). Briefly, 40 ng bisulfite-converted DNA was PCR
amplified for the ROI of the IL17A, IL17F, IFNG, RORC2, and TBX21
genes using bisulfite-DNA–specific primers (Table I) in a PCR using the
following program: 95˚C for 3 min; 50 cycles of 95˚C for 35 s, annealing
temperature (Table I) for 35 s, and 72˚C for 40 s; and a final extension at
72˚C for 10 min. Bisulfite-PCR products were then subjected to pyrose-
quencing with the primers listed in Table I. Methylation levels at CpG sites
were obtained using Pyro Q-CpG software.
RNA isolation, cDNA synthesis, and real-time quantitative
RT-PCR
Total RNA was extracted using the RNeasy Micro Kit (QIAGEN) and
treated with DNase I to eliminate possible genomic DNA contamination.
TaqMan RT-PCR was performed as described by Santarlasci et al. (20).
Primers and probes used were purchased from Life Technologies. Quan-
tification was performed on cell number.
Single-cell real-time PCR
Single cells were sorted by FACSAria and then processed using a Single Cell
to CT Kit (Life Technologies), according to the manufacturer’s instructions.
Briefly, single cells were lysed in the presence of DNase I prior to RNA
reverse transcription. cDNA was then subjected to a preamplification step,
using a panel of Taqman Gene Expression Assays (Life Technologies) of
our interest. Preamplified cDNA was then quantitated by real-time PCR
using Taqman Gene Expression Master Mix and Taqman Gene Expression
Assays (Life Technologies) on a 7900HT Instrument (Life Technologies).
Statistics
The Mann–Whitney U test was used for DNA methylation analysis; the
paired Student t test was used for mRNA expression analysis. A p value #
0.05 was considered significant.
Results
Th17-derived (nonclassic) Th1 clones acquire demethylation at
the IFNG and TBX21 but maintain hypomethylation at the
RORC2 and IL17A
We have recently shown that human Th17 cells can be shifted
in vitro into IFN-g–producing cells (that we named as nonclassic
Th1 cells) in the presence of IL-12 and/or TNF-a (4, 21, 22). We
have also found increased numbers of nonclassic Th1 cells in the
gut of patients with Crohn’s disease, the skin of psoriatic patients,
and the SF of patients suffering from JIA (9, 21, 23). Human
nonclassic Th1 can be distinguished from classic Th1 cells be-
cause of the expression of Th17 cell–associated markers, such as
CD161, CCR6, and RORC2 (10).
To define the epigenetic signatures of pure CD4+ Th cell sub-
sets, we decided to analyze DNA methylation of TBX21, RORC2,
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IFNG, IL17A, and IL17F gene loci (Table I), selected on the basis
of evolutionary conservation among species and CpG site density
in noncoding sequences (promoter and CNS) (24), in Th17, Th17/
Th1, classic Th1, and nonclassic Th1 (Th17 derived), clones
(Figs. 1, 2). As shown in Fig. 1A, we selected two ROI in the
promoter of the IL17A and IL17F genes, respectively. The analysis
of DNA methylation status of the two ROI by bisulfite pyrose-
quencing showed that Th17 and Th17/Th1 cells had a marked
demethylation, and nonclassic Th1 cells exhibited a significant
hypomethylation. In contrast, classic Th1 cells, as well as naive
CD4+ Th cells, were characterized by a complete methylation of
the above-mentioned gene loci (Fig. 1A). As shown in Fig. 1B,
two ROI in the IFNG gene locus were selected, the promoter and
CNS-1 (located 4.2 kb upstream of the transcriptional start site)
(19). The analysis of DNA methylation status of the two ROI by
bisulfite pyrosequencing showed that whereas Th17/Th1, non-
classic Th1, and classic Th1 cells had a marked demethylation,
Th17 cells and naive CD4+ Th cells were characterized by
a complete methylation (Fig. 1B). We also looked at the tran-
scription factors involved in Th17 and Th1 development, and to
this end, we analyzed one ROI for RORC2 (RORC2 downstream
(17)) and one for TBX21 (CNS-1). The analysis of DNA meth-
ylation status of the RORC2 downstream showed that whereas
Th17, Th17/Th1, and nonclassic Th1 cells had a marked demeth-
ylation, naive CD4+ Th cells and classic Th1 cells were char-
acterized by a complete methylation of this DNA region (Fig. 2A).
Of interest, the analysis of DNA methylation status of the TBX21
CNS-1 (Fig. 2B) showed that whereas nonclassic and classic Th1
cells had a marked demethylation, Th17 and Th17/Th1 cells were
hypermethylated, compared with a complete methylation in naive
CD4+ Th cells. These findings strongly support the concept that
nonclassic Th1 cells originate from Th17 cells.
To provide additional evidence for this possibility, we decided to
stimulate in vitro four Th17 clones in the presence of allogeneic
feeder cells and IL-12. As expected on the basis of the results of our
previous study (4), after 2 wk of activation, a significant proportion
of clonal cells started to produce IFN-g (Fig. 3). IL-17A+IFN-g2,
IL-17A+IFN-g+, and IL-17A2IFN-g+ cell fractions were then
obtained by cell sorting, and DNA methylation of TBX21, RORC2,
IFNG, IL17A, and IL17F gene loci was analyzed. As indicated in
Fig. 3B and 3D, all three cell fractions showed, independently of
their ability to produce IL-17A, complete demethylation of IL17A
and RORC2, and hypomethylation of IL17F ROI, demonstrating
an epigenetic imprinting of Th17 origin in these cells. Of note,
only IFN-g–producing cell subsets (IL-17A+IFN-g+ and IL-17A2
IFN-g+ cells) were characterized by a significant hypomethylation
of the IFNG promoter, when compared with cells producing IL-
17A alone (Fig. 3C). Moreover, all three cell subsets also showed
complete demethylation of the ROI in TBX21 (Fig. 3E).
To understand whether the acquisition of the nonclassic Th1
phenotype by Th17 cells was only a transient or a stable phe-
nomenon, IL-17A2IFN-g+ cell fractions were FACS sorted from
in vitro polarized Th17 clones and then cultured for an additional
2 wk under neutral (medium alone) or Th17-polarizing (IL-1b plus
IL-23 or IL-1b plus IL-6 plus IL-23 plus TGF-b) conditions.
Irrespective of the different culture conditions, the totality of the
cells was able to produce IFN-g, as assessed at the single-cell level
upon PMA plus ionomycin stimulation (data not shown). Ac-
cordingly, as shown in Fig. 3F, methylation analysis of the IFNG
promoter and CNS-1 of cells cultured under Th17 polarizing con-
ditions clearly showed stability of the demethylated status.
RORC2 is methylated in classic, but hypomethylated in
nonclassic, ex vivo Th1 cells derived from both normal and
inflamed tissues
To confirm these findings obtained on T cell clones, we extended
our analysis in different ex vivo CD4+ Th subsets isolated from PB
by separation procedures based on both the expression of surface
markers and the ability of cells to produce different cytokines.
Th17 cells were obtained as CD4+CD161+CCR6+IL-17A+IFN-g2,
Th17/Th1 cells as CD4+CD161+CCR6+IL-17A+IFN-g+, nonclassic
Th1 cells as CD4+CD161+CCR6+IL-17A2IFN-g+, and classic Th1
cells as CD4+CD1612CCR62IL-17A2IFN-g+ cells (Fig. 4A). Be-
cause of the paucity of circulating CD4+CD161+ T cells, and to
avoid a possible modulation of the Th cell phenotype owing to
in vitro expansion, the above-mentioned cell populations were
Table I. Primer sequences
Target Region Primer Sequence 59–39 Purpose Annealing Temperature
IL-17A promoter F TTTTTTTTTAGAAGGAGAGATT Bisulfite PCR
IL-17A promoter R Biotin-TATTCCTAAATCTCCATAATC Bisulfite PCR 52˚C
IL-17A promoter sequencing 1 AGGAGAGATTTTTTTATG Pyrosequencing
IL-17A promoter sequencing 2 AAGGAGAAAAGTTTTATAA Pyrosequencing
IL-17A promoter sequencing 3 TTATTGGTGGTGAGTT Pyrosequencing
IL-17F promoter F GTGGTTTATTTTGTGTAGG Bisulfite PCR
IL-17F promoter R Biotin-ATAAATTTTCTCCCATTTAA Bisulfite PCR 52˚C
IL-17F promoter sequencing 1 GTATTTGTTAGTTTTATAGTAAT Pyrosequencing
IL-17F promoter sequencing 2 GTTTTTTTATAAATTGTTA Pyrosequencing
IFNg CNS-1 F AGAAAAGGGGGGATTTA Bisulfite PCR
IFNg CNS-1 R Biotin-TAACACTCACAACCAAATTATC Bisulfite PCR 50˚C
IFNg CNS-1 sequencing 1 GGGGATTTAGAAAAAT Pyrosequencing
IFNg CNS-1 sequencing 2 TGTATGATGTTAGGAGTTT Pyrosequencing
IFNg promoter F TGGTATAGGTGGGTATAAT Bisulfite PCR
IFNg promoter R Biotin-TTACATATAAATCCTAACAATAAC Bisulfite PCR 50˚C
IFNg promoter sequencing 1 TTATTTTAAAAAATTTGTG Pyrosequencing
IFNg promoter sequencing 2 TAATTTTTTTGGTTTAAT Pyrosequencing
Tbx21 F TGGGAAATTAGTGGTTAT Bisulfite PCR
Tbx21R Biotin-AAAAATCACCCCCTAT Bisulfite PCR 52˚C
Tbx21 sequencing 1 GGGTTTATAGTATAGTTTTT Pyrosequencing
Tbx21 sequencing 2 TTTTATTTTAGGTTTATTTATA Pyrosequencing
RORC2 F TATTGGGGGAGAGAGT Bisulfite PCR
RORC2 R Biotin-AACATCCTCCTTTCCA Bisulfite PCR 55˚C
RORC2 sequencing 1 GGAGAGAGTTAGGTGTAGA Pyrosequencing
RORC2 sequencing 2 TTGAGAAGGATAGGG Pyrosequencing
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collected from pooled buffy coats of five individual donors. To
verify the quality of cell sorting, the ex vivo–derived Th17, Th17/
Th1, nonclassic, and classic Th1 cell fractions were then analyzed
for RORC2, TBX21, IL17A, and IFNG mRNA expression. As
shown in Fig. 4B, ex vivo–derived Th17 and Th17/Th1 cells
expressed high RORC2 and IL17A, but low IFNG, as well as in-
termediate TBX21 mRNA levels, whereas classic Th1 cells were
characterized by high TBX21 and IFNG, but low RORC2 and
IL17A, mRNA levels. In contrast to classic Th1 cells, nonclassic
Th1 cells exhibited intermediate RORC2 mRNA levels (Fig. 4B).
Next, we analyzed DNA methylation of TBX21, RORC2, IFNG,
IL17A, and IL17F gene loci in these ex vivo Th17, Th17/Th1, clas-
sic, and nonclassic Th1 cell fractions. As shown in Fig. 4, ex vivo
Th17 cells exhibited a complete demethylation of the RORC2
(Fig. 4E) and IL17A (Fig. 4C) ROI, and hypomethylation of the
IL17F (Fig. 4C) and TBX21 (Fig. 4F) ROI, but hypermethylation of
the IFNG (Fig. 4D) ROI, when compared with CD4+ naive Th cells.
Ex vivo Th17/Th1 cells were characterized by hypomethylation of
all the RORC2, IL17A, IL17F, TBX21, and IFNG ROI, when com-
pared with CD4+ naive Th cells (Fig. 4C–F), in line with their mixed
phenotype. Strikingly, in contrast to classic Th1 cells, nonclassic
Th1 cells were characterized by significant hypomethylation of both
RORC2 (Fig. 4E) and IL17A ROI (Fig. 4C). In contrast, IFNG and
TBX21 ROI were almost equally demethylated on both nonclassic
and classic Th1 cells (Fig. 4D, 4F), whereas IL17F ROI was
hypermethylated on both nonclassic and classic Th1 cells (Fig. 4C).
FIGURE 1. DNA methylation analysis of IL17A, IL17F, and IFNG gene loci in T cell clones with different Th phenotypes. Alignment of human and
mouse genomes at IL17A, IL17F (A), and IFNG (B) gene loci was performed using Vista software (30). DNA sequence identity .50% (y-axis) over
$100 bp is indicated in the histogram plot. Arrows indicate transcription direction. Pink regions indicate conserved noncoding sequences, whereas blue
regions are conserved coding sequences (top of each panel). DNA methylation status of PB CD4+ naive T cells and of Th17, Th17/Th1, nonclassic, and
classic Th1 clones are represented as colorimetric-code (yellow-red scale). Methylation level at each CpG site is the average of three T cell clones for each
subset (middle of each panel). The distribution of the average methylation levels at each CpG site of the whole region is depicted also as a box plot for each
population. Medians and 25th and 75th percentiles are shown in boxes, lines with filled square represent the means, and minimum and maximum values are
shown as whiskers (bottom of each panel).*p # 0.05, **p # 0.01, ***p # 0.001.
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To assess the methylation status of nonclassic and classic Th1
cells in diseased patients, we isolated CD4+CD161+CCR6+IL-
17A2IFN-g+ (nonclassic Th1) cells and CD4+CD1612CCR62IL-
17A2IFN-g+ (classic Th1) cells from the SF of four JIA patients.
Unfortunately, the number of cells was insufficient to make direct
methylation analysis. For this reason, we performed quantitative
PCR analysis of TBX21, RORC2, IL17A, and IFNG on all ex vivo
isolated classic and nonclassic Th1 cells. Moreover, we analyzed
DNA methylation of TBX21, RORC2, IFNG, IL17A, and IL17F
gene loci on in vitro expanded classic and nonclassic Th1 cells
derived from two of the four JIA patients. As shown in Fig. 5A,
ex vivo nonclassic Th1 cells expressed higher IL17A and RORC2
(with the latter reaching statistical significance) but equal IFNG
and TBX21 mRNA levels, when compared with classic Th1 cells.
Accordingly, as shown in Fig. 5, 2-wk in vitro expanded non-
classic Th1 cells exhibited reduced methylation of the RORC2
(Fig. 5D), IL17A, and IL17F promoters (Fig. 5B) and IFNG CNS-1
(Fig. 5C) ROI, when compared with classic Th1 cells. No differ-
ences in the methylation of IFNG promoter (Fig. 5C) and TBX21
CNS-1(Fig. 5F) ROI were appreciable between nonclassic and
classic Th1 cells (Fig. 5).
Only a minority of human naive CD4+CD161+ cells represent
Th17 precursors
In a previous study, we showed that human Th17 cells originate
from a small population of CD4+CD161+ Th cell precursors
present in both UCB and newborn thymus (9). This small pop-
ulation of naive CD4+CD161+ T cells exhibited high RORC2,
IL23R, CCR6, and IL1R1 mRNA levels, whereas the much more
abundant CD4+CD1612 naive Th cell counterpart virtually did
not. However, the CD4+CD161+ naive Th cells were unable to
produce IL-17A, unless they were activated in vitro in the
presence of IL-23 and IL-1b, whereas the CD4+CD1612 naive
Th cells could never be induced to produce IL-17A (9). On the
basis of these findings, we decided to analyze DNA methylation
of the RORC2 gene locus in these two populations as a tool to
better define the nature of human Th17 precursors. To this end,
ex vivo UCB-derived CD4+CD161+ and CD4+CD1612 T cell
fractions were separated by cell sorting and first analyzed
for RORC2 mRNA expression. As expected, ex vivo–derived
UCB-derived CD4+CD161+ cells expressed high RORC2 mRNA
levels, whereas RORC2 mRNA levels in UCB-derived CD4+
CD1612 cells were virtually undetectable (Fig. 6A). Surpris-
ingly, however, RORC2 ROI was hypermethylated similarly in
both CD4+CD161+ and CD4+CD1612 UCB-derived populations
(Fig. 6B).
To explain this apparent contradiction, we hypothesized that
only a small minority of thewhole population of CD4+CD161+ naive
Th cells was expressing RORC2. To provide experimental support
for this hypothesis, we performed PCR analysis of RORC2,
IL23R, IL1R1, and on ex vivo UCB-derived CD4+CD161+ and CD4+
CD1612 cells even at the single-cell level.
This approach was used because bisulfite analysis cannot be
performed on single cells; however, it is reasonable to speculate
that the detection on a single cell of a given mRNA can be con-
sidered a sign of permissive methylation status of the gene locus in
the same cell. Therefore, single-cell PCR analysis was performed
on a total number of 100 cells from ex vivo UCB-derived CD4+
FIGURE 2. DNA methylation analysis of RORC2 and TBX21 gene loci in T cell clones with different Th phenotype. Alignment of human and mouse
genomes at RORC2 (A) and TBX21 (B) gene loci was performed as described in Fig. 1. DNA methylation status of PB CD4+ naive T cells and of Th17,
Th17/Th1, nonclassic, and classic Th1 clones are represented as colorimetric-code (yellow-red scale). Methylation level at each CpG site is the average of
three T cell clones for each subset (middle of each panel). The distribution of the average methylation levels at each CpG site of the whole region is
depicted also as a box plot for each population. Medians and 25th and 75th percentiles are shown in boxes, lines with filled square represent the means, and
minimum and maximum values are shown as whiskers (bottom of each panel). **p # 0.01, ***p # 0.001.
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CD161+ and CD4+CD1612 cells (50 cells for each cell subset
from two different donors). Data obtained on UCB bulk cells
subsets confirmed our previous observations (9, 11), that is, that
RORC2, IL23R, CCR6, and IL1R1 mRNA was highly expressed
on CD4+CD161+ compared with CD4+CD1612 cell fractions
(Fig. 6C). Moreover, single-cell PCR analysis revealed that only
a fraction of CD4+CD161+ cells expressed the analyzed mRNA
and indicated a frequency of RORC2-expressing cells of 25%
(CB1 = 18%, CB2 = 32%) in the CD4+CD161+ cell fraction and of
0% (CB1 = 0%, CB2 = 0%) in the CD4+CD1612 counterpart
(Fig. 6D and data not shown). In addition, 5% (CB1 = 4%, CB2 =
6%) of the CD4+CD161+ cells analyzed expressed IL23R and none of
them expressed IL1R1 and CCR6 (Fig. 6D and data not shown). None
of the CD4+CD1612 T cells expressed IL23R, IL1R1, or CCR6
(Fig. 6D and data not shown). Of note, all the few cells expressing
IL23R were contained in the RORC2-positive cell fraction (Fig. 7).
FIGURE 3. Demethylation of the IFNG promoter accompanies Th17 polarization toward the Th17/Th1 phenotype. Four selected pure Th17 cell clones were
polarized in vitro toward Th1 by culturing in the presence of allogeneic feeder cells and the pro-Th1 cytokine IL-12 for 2 wk. (A) Cytokine production was
evaluated by intracellular staining after PMA plus ionomycin stimulation before and after polarization. On day 15, cells were sorted on the basis of their
cytokine profile. The IL-17A2IFN-g+ fraction of three of the above-mentioned Th1-polarized Th17 clones was then cultured in medium alone or in
Th17-favoring conditions (IL-1b and IL-23 or IL-1b, IL-6, IL-23, and TGF-b) for 2 additional weeks. DNA methylation status at IL17A and IL17F (B),
IFNG (C and F), RORC2 (D), and TBX21 (E) genes in the indicated cell subsets or culture conditions was represented as colorimetric-code (yellow-red
scale). Methylation level at each CpG site is the average of three or four T cell clones for each subset (middle of each panel). The distribution of the
average methylation levels at each CpG site of the whole region is depicted also as a box plot for each population. Medians and 25th and 75th per-
centiles are shown in boxes, lines with filled square represent the means, and minimum and maximum values are shown as whiskers (bottom of each
panel). *p # 0.05.
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FIGURE 4. Ex vivo–derived cytokine-producing Th cells exhibit the same DNA methylation status of T cell clones. (A) Sorting strategy for the
isolation of CD4+CCR6+CD161+IL-17A+IFN-g2, CD4+CCR6+CD161+IL-17A+IFN-g+, CD4+CCR6+CD161+IL-17A2IFN-g+, CD4+CCR62CD1612
IL-17A2IFN-g+ T cell populations from PB MNC. One of five is depicted. CD4+ cells were negatively selected from PB MNC and then further
divided into CCR6+ and CCR62 populations by MACS sorting. Afterward, these populations were stimulated with PMA plus ionomycin to perform
secretion assay, and were sorted by FACS based on IFN-g, IL-17A, and CD161 expression. (B) Real-time quantitative PCR analysis of IL17A, IFNG,
RORC2, and TBX21 mRNA levels. Columns represent means 6 SE of mRNA fg/5000 cells of the different T cell populations from five healthy
donors. DNA methylation status at IL17A and IL17F (C), IFNG (D), RORC2 (E), TBX21 (F) genes in PB CD4+ naive T cells and in the ex vivo–derived
Th cell subsets pooled from five donors, was represented as colorimetric code (yellow-red scale, top of the panel). DNA methylation levels of the
whole region are depicted also as a box plot for each population. Medians and 25th and 75th percentiles are shown in (Figure legend continues)
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Discussion
For many years, in both murine experimental models and human
diseases, Th1 cells have been thought to be responsible for
chronic inflammation and organ-specific autoimmune disorders
(25). However, this scenario has been completely changed by the
recent discovery, first in mice and then in humans, of a new
lineage of CD4+ T helper cells that produce IL-17A and express
the transcription factor RORgt (RORC2 in humans), named
Th17 (3). Several models of knockout mice provided evidence
that supports the pathogenicity of Th17 cells, whereas Th1 cells
were considered to be mainly protective at the sites of inflam-
mation (26–28). A possible answer to this question can come
from the observation that Th17 and Th1 phenotypes are not
mutually exclusive. Studies performed in our laboratory dem-
onstrated first that a portion of human IL-17A–secreting cells are
also able to simultaneously produce IFN-g (Th17/Th1 cells) and
provided evidence that both Th17 and Th17/Th1 cells can be
shifted to the production of IFN-g alone (named as nonclassic
Th1 cells) (4, 10). Following these initial findings in humans, the
Th17 cell plasticity was demonstrated even in mice (29).
boxes, lines with filled square represent the means, and minimum and maximum values are shown as whiskers (bottom of each panel). *p# 0.05, **p# 0.01,
***p # 0.001.
FIGURE 5. In vitro expanded SF-derived nonclassic Th1 cells display demethylation of RORC2 and IL17A gene loci. (A) Real-time quantitative PCR
analysis of the IL17A, IFNG, RORC2, and TBX21mRNA levels from SF-derived nonclassic and classic Th1 cells. CD4+ cells were negatively selected from
SF and then further divided into CCR6+ and CCR62 populations by MACS sorting. Afterward, these populations were stimulated with PMA plus ion-
omycin to perform secretion assay, and were sorted by FACS based on IFN-g, IL-17A, and CD161 expression. Columns represent means 6 SE of mRNA
fg/10,000 cells of the two T cell populations from four JIA patients. DNA methylation status at IL17A and IL17F (B), IFNG (C), RORC2 (D), and TBX21 (E)
genes in in vitro expanded SF-derived Th1 cell subsets pooled from two patients, was represented as colorimetric code (yellow-red scale, top of the panel).
DNA methylation levels of the whole region are depicted also as a box plot for each population. Medians and 25th and 75th percentiles are shown in boxes,
lines with filled square represent the means, and minimum and maximum values are shown as whiskers (bottom of each panel). *p # 0.05, **p # 0.01,
***p # 0.001.
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Despite the findings that support the Th17 origin of nonclassic
Th1 cells, it was recently shown that in vitro expanded human Th1
and Th17 cells, as well as intermediate Th17/Th1 cells, have distinct
epigenetic signatures at cytokine (IFNG and IL17A) and tran-
scription factor RORC2, but not at transcription factor TBX21, gene
loci (17). The results of this study were based on the isolation of
different CD4+ Th subsets from PB, thanks to the development of
a flow cytometry–based method that took advantage of the dif-
ferent expressions of CCR6, CD161, and CXCR3. CCR6+CD161+
CXCR32 CD4+ T cells were defined as Th17 cells, CCR6+
CXCR3+ cells as Th17/Th1 cells, and CCR62CXCR3+ as Th1
cells (17). However, the Th17/Th1 cells, as defined by applying the
Cohen (17) flow cytometry–based method, indeed represented
a mixed population, containing not only cells producing both IL-
17A and IFN-g but also Th17-derived (nonclassic) Th1 cells. In
addition, owing to the low numbers of cells collected from a single
donor, the different cell fractions required in vitro expansions in the
presence of autologous feeder cells for 2 wk, thus possibly causing
undesired effects of cell polarization and/or modulation.
To identify a more convincing epigenetic signature of pure Th17,
Th17/Th1, classic, and nonclassic Th1 cells, we decided to evaluate
DNAmethylation levels at cytokine (IFNG, IL17A, and IL17F) and
transcription factor (TBX21 and RORC2) gene loci of the above-
mentioned Th cell subsets obtained from four different sources: 1)
Th17, Th17/Th1, classic, and nonclassic Th1 clones; 2) IL-17A+
IFN-g2 (Th17), IL-17A+IFN-g+ (Th17/Th1), and IL-17A2IFN-g+
(nonclassic Th1) cells derived from the in vitro polarization of
a Th17 cell clone; 3) PB MNC ex vivo isolated CD4+CCR6+CD161+
IL-17A+IFN-g2 (Th17) cells, CD4+CCR6+CD161+IL-17A+IFN-g+
(Th17/Th1) cells, CD4+CCR6+CD161+IL-17A2IFN-g+ (nonclassic
Th1) cells, and CD4+CCR62CD1612IL-17A2IFN-g+ (classic Th1)
cells; and 4) in vitro expanded CD4+CCR6+CD161+IL-17A2IFN-g+
(nonclassic Th1) and CD4+CCR62CD1612IL-17A2IFN-g+ (classic
Th1) cells derived from the SF of JIA patients. The data clearly
demonstrate that Th17 cells, in agreement with their mRNA ex-
pression profile, were characterized by low methylation levels at
RORC2, IL17A, and IL17F, and by high methylation levels at IFNG,
gene loci. In accordance with their mixed phenotype, in addition to
hypomethylation of RORC2, IL17A, and IL17F gene loci, Th17/Th1
cells showed higher demethylation levels of TBX21 and IFNG gene
loci when compared with Th17 cells. Of note, nonclassic Th1, de-
rived from both PBMC of healthy subjects and SF of JIA-affected
FIGURE 6. RORC2 is expressed by a small fraction of CD4+CD161+ naive T cells. (A) Real-time quantitative PCR analysis of the mRNA levels of
RORC2 in CD4+CD161+ and CD4+CD1612 cells pooled from eight UCB samples. Columns represent means of three replicates of mRNA levels. (B) DNA
methylation status at RORC2 gene in CD4+CD161+ and CD4+CD1612 UCB cells pooled from eight donors was represented as colorimetric-code (yellow-
red scale; see previous figures). The distribution of the average methylation levels at each CpG site of the whole region is depicted also as a box plot for
each population. Medians and 25th and 75th percentiles are shown in boxes, lines with filled square represent the means, and minimum and maximum
values are shown as whiskers (bottom of each panel). (C) Real-time quantitative PCR analysis of the mRNA levels of CD161 (black column), RORC2 (dark
gray column), IL23R (gray column), CCR6 (light gray column), and IL1R1 (white column) in CD4+CD161+ and CD4+CD1612 cells was represented. One
of two different UCB analyzed is depicted. Columns represent means of three replicates of mRNA levels. (D) Single-cell real-time quantitative PCR of the
mRNA levels of CD3«, CD161, RORC2, IL23R, CCR6, and IL1R1 in CD4+CD161+ and CD4+CD1612 cells in one of two UCB analyses performed. Each
cell is represented as a diamond. Data are indicated as Ct values.
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patients, could be distinguished from classic Th1 cells not only
because of the demethylation of the RORC2 gene locus but also
because of their lower methylation levels at the IL17A gene pro-
moter. Finally, and in support of the data obtained on purified Th cell
subsets, we found that the IFN-g–secreting cell fractions derived
from the in vitro polarization of Th17 clones were characterized by
progressive IFNG promoter demethylation, whereas the RORC2
gene locus and IL17A promoter maintained a complete demethylated
status. More importantly, we demonstrated that the acquired IFNG
promoter demethylation was maintained after 2 wk of in vitro cul-
tures of the IFN-g–producing cell fraction in the presence of Th17-
polarizing cytokines.
Taken together, these data clearly establish at the molecular level
the existence of a strict relationship between Th17 and nonclassic
Th1 cells, supporting the concept that nonclassic and classic Th1
cells belong to two distinct cell lineages. Obviously, it cannot be
excluded that the activation of naive UCB Th17 precursors (CD4+
CD161+ T cells) in the presence of Th1-polarizing conditions may
induce a direct polarization of these cells toward the Th1 phe-
notype (Fig. 7). These findings also identify the demethylated
status of RORC2 and IL17A ROI as useful stable epigenetic
markers of the “Th17 membership,” in addition to the expression
of CD161 and CCR6 (8). Increased numbers of nonclassic Th1
cells have been found in patients with JIA or Crohn’s disease (21,
23), suggesting that acquisition of the ability to produce IFN-g by
Th17 cells occurs in vivo and associates with chronic inflamma-
tory responses. It seems likely that nonclassic Th1 cells can play
a pivotal role in the establishment and persistence of the disease
because their number at the level of the inflammatory sites directly
correlates with parameters of disease activity (21). Therefore,
further examination of the epigenetic profile of Th1 cells from
patients with chronic inflammatory disorders will be key to a
better understanding of their origin. This issue is also very
important from a practical point of view because the knowledge
of whether these cells are primarily pathogenic mediators or
have protective functions will help to identify which cell types
should be therapeutically targeted in a variety of diseases.
In this study, we also investigated the DNA methylation sig-
nature at the RORC2 locus in human Th17 cell precursors, which
are known to be contained within the CD4+CD161+ population of
UCB cells (9). This population displays RORC2, IL23R, CCR6,
and IL1R1 gene expression, whereas its CD1612 counterpart
virtually does not. Therefore, we assessed DNA methylation levels
at the RORC2 promoter in CD4+CD161+ and CD4+CD1612
UCB cells. Unexpectedly, comparable methylation levels between
these two cell sources were found, allowing us to hypothesize that
Th17 cell precursors expressing RORC2 are only a small fraction
of the entire CD4+CD161+ UCB population. Therefore, owing to
the impossibility of performing bisulfite sequencing on single
cells, we performed single-cell real-time PCR on CD4+CD161+
and CD4+CD1612 UCB cells. In agreement with our hypothesis,
we found that only 25% of the CD4+CD161+ cells and none of the
CD4+CD1612 cells exhibited RORC2 mRNA. Accordingly, only
20% of clones expressing RORC2 mRNA could be obtained by
culturing single CD4+CD161+ naive T cells in the presence of
IL-1b and IL-23 (data not shown). The analysis of IL23R, CCR6,
and IL1R1 mRNA levels on single cells showed that they were
expressed by none of the CD1612 cells, whereas only 5% of the
CD161+ cells expressed IL23R. Of note, all these IL23R-positive
cells were expressing RORC2. Although we were able to detect
CCR6 and IL1R1 mRNA expression on the CD161+ bulk pop-
ulation, we found no single cells expressing them, thus suggesting
a frequency of positive cells ,1%. These data identify one more
“tile in the puzzle” of Th17 cell physiology. Taken together, they
confirm that only CD4+CD161+, but not CD4+CD1612, naive Th
cells contain RORC2-expressing Th17 precursors and demonstrate
that these latter cells represent only a minority of the entire CD4+
CD161+ T cell population. This finding explains why in our pre-
vious studies (9, 11) we were unable to polarize the entire UCB-
derived CD4+CD161+ cells toward the Th17 phenotype following
their in vitro activation in the presence of IL-1b plus IL-23. This
small subset of CD4+CD161+RORC2+ cells may express IL-23R,
and perhaps also CCR6 and IL-1R1, probably in later phases of
their development, whereas they acquire the ability to produce IL-
17A only following exposure to IL-1b and IL-23 in the tissue
environment. However, currently we cannot exclude the possi-
bility that the CD4+CD161+RORC22 cells represent a still im-
mature stage, which, under certain microenviromental conditions,
may be induced to acquire the RORC2 expression (Fig. 7).
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